Catalyst Pharmaceuticals Recognized as One of North Americas Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500 List
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
About 56% of ImmunoCellular Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading ImmunoCellular Therapeutics pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with ImmunoCellular Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use ImmunoCellular Therapeutics stock news signals to limit their universe of possible portfolio assets.
ImmunoCellular |
Attributes 234 percent Revenue Growth to Operational Excellence and Strong Commercial ExecutionCORAL GABLES, Fla., Nov. 25, 2024 -- Catalyst Pharmaceuticals, Inc. , today announced it ranked number 452 on the Deloitte Technology Fast 500, a ranking of the 500 fastest-growing technology media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The 2024 Deloitte Technology Fast 500 award w
Read at finance.yahoo.com
 |
ImmunoCellular Therapeutics Fundamental Analysis
We analyze ImmunoCellular Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoCellular Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoCellular Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
ImmunoCellular Therapeutics is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
ImmunoCellular Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmunoCellular Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of ImmunoCellular Therapeutics could also be used in its relative valuation, which is a method of valuing ImmunoCellular Therapeutics by comparing valuation metrics with similar companies.
Peers
ImmunoCellular Therapeutics Related Equities
| PHGUF | Pharming Group | 1.33 | ||||
| LUMO | Lumos Pharma | 0.23 | ||||
| CPRX | Catalyst Pharmaceuticals | 0.19 | ||||
| NWBO | Northwest Biotherapeutics | 3.33 | ||||
| BOLT | Bolt Biotherapeutics | 5.36 | ||||
| CLRB | Cellectar Biosciences | 16.13 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |